Date | Price Target | Rating | Analyst |
---|---|---|---|
9/3/2024 | $175.00 | Buy | Redburn Atlantic |
7/10/2024 | $100.00 → $130.00 | Mkt Outperform | JMP Securities |
12/18/2023 | Outperform → Mkt Perform | William Blair | |
12/4/2023 | $100.00 | Outperform | TD Cowen |
9/29/2023 | Outperform | William Blair | |
3/8/2023 | $120.00 | Mkt Outperform | JMP Securities |
11/30/2022 | Outperform | SVB Leerink | |
10/13/2022 | $105.00 | Buy | Mizuho |
4 - Lantheus Holdings, Inc. (0001521036) (Reporting)
SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13D - Lantheus Holdings, Inc. (0001521036) (Filed by)
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. "We're excited to have Jamie join Lantheus as we continue to harness our team's potential to deliver innovative solutions to serve patients and healthcare professionals," said Dan Niedzwiecki, Chief Administrative Officer of Lantheus. "At Lantheus, our people drive our success, and Jamie's proven leadership and expertise will foster a collaborativ
Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Company has appointed Brian Markison, current Board Chair and industry veteran, to the position of Chief Executive Officer (CEO), effective as of March 1, 2024. He will also contin
Jones Trading analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:LNTH) with a Buy and raises the price target from $128 to $137.
FTAI Aviation Ltd. (NYSE:FTAI) and Applied Industrial Technologies, Inc. (NYSE:AIT) were among small-cap stocks moving higher on Tuesday as the Russell 2000 Index had a fifth straight day of gains. The iShares Russell 2000 ETF (NYSE:IWM) gained 3.41% on Tuesday, ushering the index to a cumulative gain of over 9% across the last five sessions. This remarkable streak represents the Russell 2000's best five-day performance since June 2020. FTAI Aviation, a provider of aircraft operations and engine maintenance, rose 5.63% to close at $107.42 on Tuesday, while Applied Industrial gained 4.63% to $210.59. Also Read: Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
Redburn Atlantic initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $175.00
JMP Securities reiterated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $130.00 from $100.00 previously
William Blair downgraded Lantheus Holdings from Outperform to Mkt Perform
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand innovative pipelineGAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share guidance driven by strategic transactions BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ:LNTH), the
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second quarter of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of Meilleur Technologies, Inc., which includes NAV-4694, expanding Lantheus' Alzheimer's disease pipeline. Through this acquisition, Lantheus now has the worldwide exclusive rights to ß amyloid PET (positron emission tomography) imaging agent, NAV-4694, also known as F18-flutafuranol. NAV-4694 is currently in Phase 3 development and is also being used in academic and industry investigational therapeutic trial
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4. To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lantheus Lant
BEDFORD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002's initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024. Title: Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC
8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
S-8 - Lantheus Holdings, Inc. (0001521036) (Filer)
144 - Lantheus Holdings, Inc. (0001521036) (Subject)